Related Experiment Video
Updated: Jul 11, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Estimating the cost of the Medicare Pharmacist Services Coverage Act of 2001
Virginia H Poole1, Donald W Moran, C Edwin Webb
1Moran Company, Fairfax, Virginia 22209, USA. vhpoole@themorancompany.com
Background:
In recent years considerable attention has focused on pharmacists' professional evolution toward patient care-oriented practice. The Pharmacist Provider Coalition (PPC), established in 2000, seeks recognition and payment for pharmacists' patient care services. Concerted effort by the PPC on this issue resulted in the introduction of the Medicare Pharmacist Services Coverage Act of 2001, which would have amended Title XVIII of the Social Security Act to create new types of covered services under Medicare and recognize pharmacist practitioners as providers. However, the legislation was not passed by the 107th Congress.
Study Objectives:
The PPC engaged The Moran Company to measure the potential net cost to the United States government of the Medicare Pharmacist Services Coverage Act of 2001, and to perform this measurement in a manner that is consistent with the cost-projection methods used by the Congressional Budget Office (CBO).
Design:
The model is anchored to the 10-year projection of revenues and spending within the federal government developed annually by the CBO. It examines the anticipated magnitude and cost of patient care services with respect to chronic disease and pharmaceutical therapy management, in both facility and nonfacility settings.
Results:
The methodology yields a final cost estimate of 427 million dollars in 2004, the first year of implementation, and a 10-year estimate of 13 billion dollars.
Conclusions:
Recognition of pharmacists as providers of selected drug therapy management services under Medicare will have a considerable financial impact. It is instructive, however, to view the 10-year cost estimate of 13 billion dollars for pharmaceutical therapy management in light of the CBO's projected 1.5 trillion dollars estimate, over the same time frame, for drug spending among the Medicare population.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Dosage Regimens: Partial Pharmacokinetic Parameters
Drug Dosing: Geriatric Patients
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Poisoning: Potential Scenarios

